(Q46909218)

26 December 2017

title

Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma (English)

1 reference

26 December 2017

Silvia Fernández de Mattos

1 reference

1 reference

object named as

Silvia Fernández De Mattos

8

0 references

author name string

José Rodríguez

1

1 reference

26 December 2017

Antonio Gutierrez

2

1 reference

26 December 2017

Andres Palacios

3

1 reference

26 December 2017

Mayda Navarrete

4

1 reference

26 December 2017

Isabel Blancas

5

1 reference

26 December 2017

Jesus Alarcón

6

1 reference

26 December 2017

María D Caballero

7

1 reference

26 December 2017

Jordi Gines

9

1 reference

26 December 2017

Jordi Martínez

10

1 reference

26 December 2017

Andres Lopez

11

1 reference

26 December 2017

language of work or name

1 reference

1 November 2007

1 reference

26 December 2017

published in

Leukemia & Lymphoma

1 reference

26 December 2017

volume

48

1 reference

26 December 2017

issue

11

1 reference

26 December 2017

page(s)

2172-2178

1 reference

26 December 2017

https://api.crossref.org/works/10.1080%2F10428190701618268

1 reference

Current treatment approaches for mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Stem cell transplantation for mantle cell lymphoma: if, when and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Gemcitabine for relapsed or resistant lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Integrating monoclonal antibodies into the management of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Gemcitabine and oxaliplatinum: an effective regimen in a patient with progressive refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701618268

10.1080/10428190701618268

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

17990179

1 reference

26 December 2017